Literature DB >> 9802683

Cytokines in leprosy, II. Effect of treatment on serum cytokines in leprosy.

A D Moubasher1, N A Kamel, H Zedan, D D Raheem.   

Abstract

BACKGROUND: Multidrug therapy (MDT) causes a decrease in the bacterial burden in leprosy patients. Does the decrease in the antigenic stimulation of the immune system have an effect on cytokine production?
METHODS: The effect of treatment on serum cytokines was evaluated in 36 leprosy patients and 35 reactional leprosy patients and compared with that in 20 age- and sex-matched healthy individuals. The enzyme-linked immunosorbent assay (ELISA) technique was used to measure serum levels of interleukin-2 receptor (IL-2R), interleukin-10 (IL-10), and interleukin-1beta (IL-1beta) before and after treatment. These cytokines represent T-helper 1 (TH1), T-helper 2 (TH2), and macrophage cytokines, respectively.
RESULTS: The studied serum cytokines were significantly reduced after 1 year of treatment in leprosy patients. The degrees of reduction were significantly positively correlated with a reduction in the bacterial index (BI) and morphologic index (MI). After 1 year of MDT (but not 6 months), paucibacillary (PB) patients showed a significant reduction in all the studied serum cytokines to levels comparable with those of healthy controls. Multibacillary (MB) patients also showed a significant reduction in all the studied serum cytokines, but the levels were still significantly higher than those of healthy controls. Leprosy patients with high levels of serum IL-1beta were more susceptible to the development of reactions after the initiation of treatment. Corticosteroid therapy of reactional patients resulted in a significant reduction in the studied serum cytokines to levels similar or lower than those of nonreactional leprosy patients. The dose of steroids showed a significant positive correlation with the amount of decrease in IL-1beta.
CONCLUSIONS: MDT caused a reduction in serum cytokines correlated with a reduction in the bacterial burden. It is advisable to continue MDT for PB patients for 1 year. Serum IL-1beta levels may have a prognostic value for the susceptibility of leprosy patients to the development of reactions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9802683     DOI: 10.1046/j.1365-4362.1998.00382.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  6 in total

Review 1.  Immune restoration inflammatory syndromes: apparently paradoxical clinical events after the initiation of HAART.

Authors:  Matthias Stoll; Reinhold E Schmidt
Journal:  Curr HIV/AIDS Rep       Date:  2004-09       Impact factor: 5.071

Review 2.  [Immune restoration inflammatory syndromes].

Authors:  M Stoll; H Heiken; G M N Behrens; R E Schmidt
Journal:  Internist (Berl)       Date:  2004-08       Impact factor: 0.743

3.  Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions.

Authors:  A Iyer; M Hatta; R Usman; S Luiten; L Oskam; W Faber; A Geluk; P Das
Journal:  Clin Exp Immunol       Date:  2007-11       Impact factor: 4.330

4.  Serial measurement of the circulating levels of tumour necrosis factor and its soluble receptors 1 and 2 for monitoring leprosy patients during multidrug treatment.

Authors:  Rosane Dias Costa; Vanessa Amaral Mendonça; Frederico Marianetti Soriani; Sandra Lyon; Rachel Adriana Penido; Ana Maria Duarte Dias Costa; Marina Dias Costa; Fabio de Souza Terra; Mauro Martins Teixeira; Carlos Mauricio de Figueiredo Antunes; Antonio Lúcio Teixeira
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-12       Impact factor: 2.743

Review 5.  A Systematic Review of Immunological Studies of Erythema Nodosum Leprosum.

Authors:  Anastasia Polycarpou; Stephen L Walker; Diana N J Lockwood
Journal:  Front Immunol       Date:  2017-03-13       Impact factor: 7.561

6.  Polymorphisms in genes TLR1, 2 and 4 are associated with differential cytokine and chemokine serum production in patients with leprosy.

Authors:  Nadja de Lima Santana; Jamile Leão Rêgo; Joyce Moura Oliveira; Lucas Frederico de Almeida; Marcos Braz; Lídia Maria Medeiros Machado; Paulo Roberto Lima Machado; Léa Cristina Castellucci
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-03-02       Impact factor: 2.743

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.